Information Provided By:
Fly News Breaks for June 19, 2018
VRX, AMPH
Jun 19, 2018 | 12:43 EDT
After Amphastar (AMPH) announced that the FDA approved its therapeutically equivalent generic of Valeant's (VRX) Isuprel, Wells Fargo analyst David Maris said he will discuss this with management when he meets them later today but his preliminary estimate is that this generic has a sales opportunity of $10M-$25M. Maris has an Outperform rating on Amphastar shares.
News For AMPH;VRX From the Last 2 Days
There are no results for your query AMPH;VRX